Li-min Zhao
Shenzhen, 518110, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.
Journal: Frontiers in endocrinology
Published: November 30, 2021
Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis.
Journal: Frontiers in cardiovascular medicine
Published: September 16, 2021
Letter Regarding "Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR".
Journal: Kidney international reports
Published: September 15, 2021
Long-term cardiorenal efficacy of finerenone in patients with chronic kidney disease and type 2 diabetes.
Journal: Annals of palliative medicine
Published: September 11, 2021
Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?
Journal: Pharmacological research
Published: September 01, 2021
Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Journal: Frontiers in pharmacology
Published: August 01, 2021
Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials.
Journal: Frontiers in endocrinology
Published: July 19, 2021
Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial.
Journal: Therapeutic advances in endocrinology and metabolism
Published: May 14, 2021
Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF.
Journal: Cardiovascular drugs and therapy
Published: May 13, 2021
Last Updated: 09/26/2026